A PRO assessment was performed on the four identified risks. For each of the risks the estimated cost of mitigating the risk (investment) was determined; the enterprise net present value (NPV) protected was calculated given the investment was made; and, the investment productivity (a.k.a return on investment) for each investment was calculated. The following table summarizes this information. Risk Investment $(Millions) 2 15 NPV Protected $(Millions) 120 Unreported Adverse Effects FDA Hold for Adverse Effects Delay in Clinical Trial Enrollment Rewrite FDA Submission Investment Productivity 55.70 18.65 128.50 25.10 335 550 4 3 88 c) If the top three most productive investments were approved for implementation, what would be the total investment and how much enterprise value would be protected as measured in NPV